TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

JPMorgan raised the firm’s price target on Ascendis Pharma (ASND) to $167 from $165 and keeps an Overweight rating on the shares. The analyst ...

Its EC approval came in 2022. Presentation slide 10 describes its revenue and planned development: Its hypoparathyroidism therapy, YORVIPATH (Palopegteriparatide, developed as TransCon PTH ...

JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...

A webcast replay will also be available COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed ...

The company has already demonstrated the value of its technology in two approved products, namely Yorvipath (palopegteriparatide), a modified version of parathyroid hormone (PTH), which is for the ...

the company has launched it as Yorvipath in Germany and Austria and is expecting a second verdict from the US regulator by 14th May. Entera Bio, meanwhile, has an oral formulation of PTH called ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including ...

Posdinemab is the second tau-directed investigational therapy by J&J that has received fast track designation from FDA this year for Alzheimer’s disease. The final guidance is a revision of a policy ...

Dr. Hojo is an Instructor in the Department of Pediatrics, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Japan. Dr. August is an Associate Professor of Medicine and ...